IAM · Iambic Therapeutics, Inc. · Investor Relations

SAN DIEGO --(BUSINESS WIRE)--Oct. 14, 2026-- Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering of 9,375,000 shares of common stock

In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intracranial tumors in a preclinical model IAM217 was designed using Iambic's

Enchant v3 is the next generation of Iambic’s multimodal transformer model, trained using 41 billion parameters on more than 6,000 molecular properties across 16 biomedical data modalities Enchant v3 ingests diverse datasets, deploys a mixture-of-experts architecture, and tests multiple

− Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology ‍ − Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic’s molecular superintelligence platform with AbbVie’s

Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’s research and development portfolio by harnessing AI to accelerate drug

San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recognize the most innovative and fast-growing private companies reshaping the

Iambic to Participate in Upcoming Investor Conferences SAN DIEGO, CA – May 11, 2026 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced its participation in upcoming investor conferences: Bank of America

SAN DIEGO, CA – April 2, 2026 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven drug discovery and development platform, today announced its participation in upcoming investor conferences: Needham Virtual Healthcare Conference: April

SAN DIEGO, CA – March 2, 2026 -- Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven drug discovery platform, today announced its participation in upcoming March investor conferences: Leerink Partners Global Healthcare Conference: March

Multi-year partnership will utilize Iambic’s broad suite of AI drug discovery technologies and wet lab capabilities to advance collaboration programs initially in Takeda’s Oncology and Gastrointestinal and Inflammation Therapeutic Areas Iambic to provide Takeda access to NeuralPLexer, Iambic’s